



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
**Fax:** (877) 208-7428      **Phone:** (800) 745-7318

## Lipid-Lowering Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist).

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M      Member's place of residence  home  nursing facility

### Medication information

#### Statins

- Altoprev (lovastatin extended-release)
- atorvastatin > quantity limits
- atorvastatin/amlodipine
- Ezallor (rosuvastatin sprinkle capsule)
- fluvastatin
- fluvastatin extended-release
- Livalo (pitavastatin calcium)
- lovastatin > quantity limits
- pravastatin > quantity limits
- rosuvastatin > quantity limits
- simvastatin > quantity limits
- simvastatin/ezetimibe > quantity limits
- Zypitamag (pitavastatin magnesium)

#### Fibric Acids

- fenofibrate tablet 40 mg, 120 mg

**Dose, frequency, and duration of requested medication** \_\_\_\_\_ **Quantity requested per month** \_\_\_\_\_

#### Indication (Check all that apply.)

- Atherosclerotic cardiovascular (CV) disease
- CV risk reduction
- Heterozygous familial hypercholesterolemia
- Homozygous familial hypercholesterolemia
- Hypercholesterolemia

#### Miscellaneous Agents

- Evkeeza (evinacumab-dgnb)
- icosapent ethyl
- Juxtapid (lomitapide)
- Nexletol (bempedoic acid)
- Nexlizet (bempedoic acid/ezetimibe)

#### PCSK9 Inhibitors

- Praluent (alirocumab)
- Repatha (evolocumab)

#### Other Lipid-Lowering Agents

Other\* \_\_\_\_\_

*\*If request is for a non-preferred brand name or generic product, please attach supporting documentation (e.g., copies of medical records and/or office notes regarding adverse reaction or inadequate response to the preferred product).*

- Hypercholesterolemia with previous history of any cardiovascular event
- Hypertriglyceridemia
- Mixed dyslipidemia
- Other. Specify pertinent medical history, diagnostic studies, and/or laboratory results.

**Please indicate prescriber specialty.**

Cardiology  Other \_\_\_\_\_

Specialist consult details (if the prescriber submitting the request is not a specialist)

Name(s) of the specialist(s) \_\_\_\_\_

Date(s) of last visit or consult \_\_\_\_\_

Contact Information \_\_\_\_\_

Is this member a referral candidate for care coordination?  Yes  No

If yes, MassHealth will offer care coordination services to this member. Please describe which additional behavioral health services would be beneficial.

**Lab Values and Treatment Plan: Please complete for all requests.**

1. Is this a request for treatment initiation?

Yes. Please provide the current baseline laboratory values.

Date \_\_\_\_\_

Total cholesterol \_\_\_\_\_ mg/dl      LDL/LDL-C \_\_\_\_\_ mg/dl

HDL \_\_\_\_\_ mg/dl      Triglycerides \_\_\_\_\_ mg/dl

No

2. Is this a request for continuation of treatment?

Yes. Please provide the current laboratory values following treatment demonstrating efficacy of the requested agent.

Date \_\_\_\_\_

Total cholesterol \_\_\_\_\_ mg/dl      LDL/LDL-C \_\_\_\_\_ mg/dl

HDL \_\_\_\_\_ mg/dl      Triglycerides \_\_\_\_\_ mg/dl

No

3. Please summarize treatment goals including target cholesterol levels.

\_\_\_\_\_  
\_\_\_\_\_

**Section I. Please complete if this request is for Altoprev, atorvastatin/amlodipine, fluvastatin, fluvastatin extended-release, Livalo, or Zypitamag.**

1. Has the member had an inadequate response to rosuvastatin at a dose of at least 40 mg/day for at least three months?  Yes  No

2. Has the member tried rosuvastatin and had an adverse reaction?

Yes. Please explain. \_\_\_\_\_  No

3. Does the member have a contraindication to rosuvastatin?

Yes. Please explain. \_\_\_\_\_  No

**Section II. Please complete if this request is for quantities above quantity limits.**

Please attach documentation of the clinical rationale for the requested dose, quantity, and frequency, including a detailed treatment plan. Specify pertinent medical history, diagnostic studies, and/or lab results.

**Section III. Please complete if this request is for fenofibrate tablet 40 mg or 120 mg.**

Please attach medical records documenting failure with a therapeutically equivalent fenofibrate formulation.

---

**Section IV. Please complete if this request is for icosapent ethyl for hypertriglyceridemia (not inclusive of those with established cardiovascular disease (CVD) or diabetes mellitus and CV risk factors).**

1. Has the member had a trial with omega-3 acid ethyl esters?
- Yes. Please list the dose and frequency, dates/duration of trial, and outcome below.  
Dose and frequency \_\_\_\_\_ Dates/duration of use \_\_\_\_\_  
Did the member experience any of the following?  Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.  
\_\_\_\_\_
- No. Please document if there is a contraindication to omega-3 acid ethyl esters.  
\_\_\_\_\_
2. Has the member had a trial with a fibric acid derivative?
- Yes. Please list the drug name, dose and frequency, dates/duration of trials, and outcomes below.  
Drug name \_\_\_\_\_ Dose and frequency \_\_\_\_\_ Dates/duration of use \_\_\_\_\_  
Did the member experience any of the following?  Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.  
\_\_\_\_\_
- No. Please document if there is a contraindication to all fibric acid derivatives.  
\_\_\_\_\_

---

**Section V. Please complete if this request is for icosapent ethyl for cardiovascular risk reduction.**

1. Does the member have established cardiovascular disease (CVD)?
- Yes. Please describe. \_\_\_\_\_
- No
2. Does the member have diabetes mellitus with at least two risk factors for CVD?
- Yes. Please describe. \_\_\_\_\_
- No
3. Will icosapent ethyl will be used in combination with a statin?
- Yes
- No. Clinical rationale why member cannot take a statin. \_\_\_\_\_

---

**Section VI. Please complete if this request is for Praluent or Repatha.**

1. Has the member had an inadequate response to rosuvastatin at a dose of at least 40 mg/day in combination with ezetimibe at a dose of at least 10 mg/day for at least the past three months?
- Yes. Please note: Requests will be evaluated taking into account MassHealth pharmacy claims history or additional documentation addressing adherence to this agent.
- rosuvastatin  
Dose and frequency \_\_\_\_\_ Dates of use \_\_\_\_\_ Outcome \_\_\_\_\_
- ezetimibe  
Dose and frequency \_\_\_\_\_ Dates of use \_\_\_\_\_ Outcome \_\_\_\_\_
- No
2. Has the member tried rosuvastatin and had an adverse reaction or does the member have a contraindication to this agent?
- Yes. Please explain. \_\_\_\_\_  No

3. Has the member tried ezetimibe and had an adverse reaction or does the member have a contraindication to this agent?  
 Yes. Please explain. \_\_\_\_\_  No
4. Will the requested agent be used in combination with a statin?  
 Yes. Please note: Requests will be evaluated taking into account MassHealth pharmacy claims history or additional documentation addressing adherence to this agent.  
 No. Please explain. \_\_\_\_\_
5. If this is a request for continuation of treatment, has the member been adherent to the lipid-lowering regimen?  
 Yes. Please note: Continued approval of the requested agent will be contingent upon MassHealth pharmacy claims history or additional documentation addressing adherence to the entire lipid-lowering regimen.  
 No

**Section VII. Please complete if this request is for Ezallor.**

Has the member had a trial with rosuvastatin tablet?

- Yes. Please list the dates/duration of trial and outcomes below.

Dates/duration of use \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.  
 \_\_\_\_\_

- No. Please document if there is a medical necessity for the use of a sprinkle capsule formulation.  
 \_\_\_\_\_

**Section VIII. Please complete if this request is for Nexletol or Nexlizet.**

1. Has the member had an inadequate response to atorvastatin at a dose of at least 80 mg/day or rosuvastatin at a dose of at least 40 mg/day in combination with ezetimibe for at least the past three months?  
 Yes. Please note: Requests will be evaluated taking into account MassHealth pharmacy claims history or additional documentation addressing adherence to this agent.  
 atorvastatin or rosuvastatin  
 Drug name \_\_\_\_\_ Dose and frequency \_\_\_\_\_  
 Dates of use \_\_\_\_\_ Outcome \_\_\_\_\_  
 ezetimibe  
 Dose and frequency \_\_\_\_\_ Dates of use \_\_\_\_\_ Outcome \_\_\_\_\_  
 No
2. Has the member tried atorvastatin and had an adverse reaction or does the member have a contraindication to this agent?  
 Yes. Please explain. \_\_\_\_\_  No
3. Has the member tried rosuvastatin and had an adverse reaction or does the member have a contraindication to this agent?  
 Yes. Please explain. \_\_\_\_\_  No
4. For Nexletol, has the member tried ezetimibe and had an adverse reaction or does the member have a contraindication to this agent?  
 Yes. Please explain. \_\_\_\_\_  No

5. Will the requested agent be used in combination with a statin?  
 Yes. Please note: Requests will be evaluated taking into account MassHealth pharmacy claims history or additional documentation addressing adherence to this agent.  
 No. Please explain. \_\_\_\_\_

---

**Section IX. Please complete if this request is for Juxtapid.**

1. Please attach laboratory testing results confirming genetic mutation associated with homozygous familial hypercholesterolemia including low density lipoprotein receptor mutations, PCSK9 mutations, and familial defective apoB mutations.
2. Has the member had an inadequate response to rosuvastatin at a dose of at least 40 mg/day for at least three months?  Yes  No
3. Has the member tried rosuvastatin and had an adverse reaction?  
 Yes. Please explain. \_\_\_\_\_  No
4. Does the member have a contraindication to rosuvastatin?  
 Yes. Please explain. \_\_\_\_\_  No
5. Has the member had a trial of LDL-C apheresis?  
 Yes. Please document outcome below.  
Did the member experience any of the following?  
 Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.  
\_\_\_\_\_  
 No. Please document if there is a contraindication to LDL-C apheresis.  
\_\_\_\_\_
6. Has the member had a trial with an additional non-statin lipid lowering agent?  
 Yes. Please list the drug name, dose and frequency, dates/duration of trials, and outcomes below.  
Drug name \_\_\_\_\_ Dose and frequency \_\_\_\_\_ Dates/duration of use \_\_\_\_\_  
Did the member experience any of the following?  
 Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.  
\_\_\_\_\_  
 No. Please document if there is a contraindication to all non-statin lipid lowering agents.  
\_\_\_\_\_
7. Will the requested agent be used in combination with a high-intensity statin?  
 Yes. Please list the drug name and dose and frequency below.  
Drug name \_\_\_\_\_ Dose and frequency \_\_\_\_\_  
 No. Please explain. \_\_\_\_\_

---

**Section XI. Please complete if this request is for Evkeeza.**

1. Please attach laboratory testing results confirming genetic mutation associated with homozygous familial hypercholesterolemia including low density lipoprotein receptor mutations, PCSK9 mutations, and familial defective apoB mutations.
2. Please provide member's current weight \_\_\_\_\_ Date \_\_\_\_\_
3. Will the requested agent be used in combination with a high-intensity statin, ezetimibe, and a PCSK9 inhibitor?  
 Yes. Please list the drug name and dose and frequency below.  
Drug name \_\_\_\_\_ Dose and frequency \_\_\_\_\_  
 No. Please explain. \_\_\_\_\_

4. If this is a request for continuation of treatment, has the member been adherent to the lipid-lowering regimen?
- Yes. Please note: Continued approval of the requested agent will be contingent upon MassHealth pharmacy claims history or additional documentation addressing adherence to the entire lipid-lowering regimen.
- No

---

**Section XII. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.**

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

---

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_  
NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_  
DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
E-mail address \_\_\_\_\_  
Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

\* *Required*

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_